Becton, Dickinson and Company (NYSE:BDX) Shares Sold by WASHINGTON TRUST Co

WASHINGTON TRUST Co trimmed its position in Becton, Dickinson and Company (NYSE:BDX) by 1.1% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 76,094 shares of the medical instruments supplier’s stock after selling 833 shares during the period. WASHINGTON TRUST Co’s holdings in Becton, Dickinson and Company were worth $18,346,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently modified their holdings of BDX. Livelsberger Financial Advisory acquired a new stake in shares of Becton, Dickinson and Company in the third quarter worth $26,000. Sound Income Strategies LLC boosted its position in Becton, Dickinson and Company by 35.8% in the 3rd quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock worth $40,000 after purchasing an additional 44 shares in the last quarter. Opal Wealth Advisors LLC purchased a new stake in Becton, Dickinson and Company in the 2nd quarter worth approximately $45,000. Abound Wealth Management increased its holdings in shares of Becton, Dickinson and Company by 96.0% during the 2nd quarter. Abound Wealth Management now owns 196 shares of the medical instruments supplier’s stock valued at $46,000 after purchasing an additional 96 shares in the last quarter. Finally, Chilton Capital Management LLC lifted its stake in shares of Becton, Dickinson and Company by 1,233.3% in the 2nd quarter. Chilton Capital Management LLC now owns 200 shares of the medical instruments supplier’s stock valued at $47,000 after purchasing an additional 185 shares during the period. Institutional investors and hedge funds own 86.97% of the company’s stock.

Becton, Dickinson and Company Stock Performance

Shares of BDX traded down $1.07 during mid-day trading on Wednesday, hitting $236.44. 141,983 shares of the company’s stock were exchanged, compared to its average volume of 1,368,582. Becton, Dickinson and Company has a fifty-two week low of $218.75 and a fifty-two week high of $259.92. The business’s 50 day moving average is $237.58 and its two-hundred day moving average is $235.04. The company has a current ratio of 1.85, a quick ratio of 1.36 and a debt-to-equity ratio of 0.70. The firm has a market capitalization of $68.33 billion, a P/E ratio of 52.31, a P/E/G ratio of 1.79 and a beta of 0.42.

Becton, Dickinson and Company (NYSE:BDX) last issued its earnings results on Thursday, August 1st. The medical instruments supplier reported $3.50 earnings per share for the quarter, beating the consensus estimate of $3.31 by $0.19. The business had revenue of $4.99 billion for the quarter, compared to the consensus estimate of $5.08 billion. Becton, Dickinson and Company had a net margin of 7.13% and a return on equity of 14.49%. The business’s quarterly revenue was up 2.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.96 earnings per share. On average, equities analysts expect that Becton, Dickinson and Company will post 13.11 earnings per share for the current year.

Analysts Set New Price Targets

BDX has been the topic of a number of analyst reports. Raymond James dropped their target price on Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating on the stock in a research report on Friday, August 2nd. Evercore ISI boosted their price target on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. Citigroup upgraded Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $255.00 to $275.00 in a report on Tuesday, October 1st. StockNews.com upgraded Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Thursday, August 8th. Finally, Stifel Nicolaus upped their price objective on shares of Becton, Dickinson and Company from $270.00 to $280.00 and gave the stock a “buy” rating in a report on Friday, July 26th. Nine research analysts have rated the stock with a buy rating, According to MarketBeat.com, Becton, Dickinson and Company currently has a consensus rating of “Buy” and a consensus price target of $282.63.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.